Description

shRNA expression vectors are designed with antibiotic markers, enabling long-lasting inhibition of target gene expression in cells. They offer a sustainable solution for maintaining gene silencing over extended periods, even reaching weeks or more. For cases where prolonged gene silencing is required using a known effective siRNA sequence, such as those obtained through siRNA synthesis screening, the utilization of the shRNA vector system is highly recommended. Our dedication lies in providing cutting-edge and user-friendly tools tailored for shRNA applications. Recently, we have introduced a new generation of highly efficient and ready-to-use shRNA expression plasmids. These innovative vectors allow for the continuous production of shRNAs within cells, achieving the desired long-term suppression of target gene expression.

Advantages

• Enhanced In Vivo Inhibition: Our shRNA expression vectors exhibit superior inhibition effects in vivo compared to conventionally synthesized siRNA. They also work synergistically with tissue-specific promoters for targeted localization.
• Inducible Expression Capability: Researchers can establish an inducible expression system using our shRNA expression vector service, providing precise control over siRNA expression.
• Effortless Cell Enrichment: By incorporating antibiotic resistance markers, our vectors facilitate the elimination of non-transfected cells, allowing for the easy enrichment of cells with silencing potential.
• Long-Term Interference: Our shRNA expression vectors enable the generation of stable cell lines, ensuring sustained and effective RNA interference over an extended period.
• Convenient Experimental Handling: We deliver our shRNA expression vectors in plasmid form, which offers enhanced stability and simplified handling compared to conventionally synthesized siRNA. Additionally, the vectors are reusable, providing added convenience for our customers.
• Competitive Pricing: The reusability of our shRNA expression vectors reduces the cost of high-throughput applications, catering to the substantial demands of siRNA customers.
• Suitable for Gene Therapy: shRNA constructs integrated into viral vectors can be employed to infect core cell lines, opening avenues for gene therapy applications.

Deliverable

• 2-5 μg of lyophilized plasmid DNA (low-copy 1-2 μg of lyophilized plasmid DNA)
• Sequencing chromatograms (electronic version in ABI file format)
• Certificate of Analysis (electronic version)
• Gene sequence alignment files (electronic version)

Related: 

• Top-notch Grade Plasmid Preparation Service (ET levels ≤0.005 EU/μg)
• Medicine-like Grade Plasmid Preparation Service (ET levels＜10 EU/mg)
• Transfection Grade Plasmid Preparation Service (ET levels＜100EU/mg)
• Research Grade Plasmid Preparation Service